Oppenheimer reiterates Outperform on UroGen Pharma stock

UroGen Pharma Stock Maintains Positive Outlook Analysts at Oppenheimer have reaffirmed their Outperform rating for UroGen Pharma, indicating a continued optimistic view of the company's stock performance. This rating decision is based on the firm's assessment of UroGen Pharma's business prospects and market trends. The stock remains a recommended buy for investors seeking potential growth opportunities.